The company is developing small molecule drugs to treat patients suffering from neurodegenerative diseases such as Parkinson’s Disease and Alzheimer’s Disease.
Previously, Mr. Butera spent 10 years as director and vice president of clinical operations at Pain Therapeutics. He was also vice president of clinical operations at Attenua and held the same role at Afferent before it was acquired by Merck & Co in 2016.
Mr. Butera’s experience will be pivotal to the company’s clinical development program, which “focuses on restoration of lost neurological function” by receptor activation in the brain, according to Anthony Ford, PhD, CEO of CuraSen.
More articles on devices:
‘A dream come true’: Dr. Jorge Chahla strives for success at Rush
New York hospital invests $2M in imaging system for spine, brain — 4 things to know
What Stryker’s spine division stands to gain from 5 acquisitions
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.